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How Well Does the New Lung Cancer Staging System
Predict for Local/Regional Recurrence After Surgery?
A Comparison of the TNM 6 and 7 Systems
Joseph M. Pepek, MD,* Junzo P. Chino, MD,* Lawrence B. Marks, MD,† Thomas A. D’Amico, MD,‡
David S. Yoo, MD, PhD,* Mark W. Onaitis, MD,‡ Neal E. Ready, MD, PhD,§ Jessica L. Hubbs, BA,†
Jessamy Boyd, MD, and Chris R. Kelsey, MD*
Introduction: To evaluate how well the tumor, node, metastasis
(TNM) 6 and TNM 7 staging systems predict rates of local/regional
recurrence (LRR) after surgery alone for non-small cell lung cancer.
Methods: All patients who underwent surgery for non-small cell
lung cancer at Duke between 1995 and 2005 were reviewed. Those
undergoing sublobar resections, with positive margins or involve-
ment of the chest wall, or those who received any chemotherapy or
radiation therapy (RT) were excluded. Disease recurrence at the
surgical margin, or within ipsilateral hilar and/or mediastinal lymph
nodes, was considered as a LRR. Stage was assigned based on both
TNM 6 and TNM 7. Rates of LRR were estimated using the
Kaplan-Meier method. A Cox regression analysis evaluated the
hazard ratio of LRR by stage within TNM 6 and TNM 7.
Results: A total of 709 patients were eligible for the analysis.
Median follow-up was 32 months. For all patients, the 5-year
actuarial risk of LRR was 23%. Conversion from TNM 6 to TNM 7
resulted in 21% stage migration (upstaging in 13%; downstaging in
8%). Five-year rates of LRR for stages IA, IB, IIA, IIB, and IIIA
disease using TNM 6 were 16%, 26%, 43%, 35%, and 40%,
respectively. Using TNM 7, corresponding rates were 16%, 23%,
37%, 39%, and 30%, respectively. The hazard ratios for LRR were
statistically different for IA and IB in both TNM 6 and 7 but were
also different for IB and IIA in TNM 7.
Conclusions: LRR risk increases monotonically for stages IA to IIB
in the new TNM 7 system. This information might be valuable when
designing future studies of postoperative RT.
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Despite decreasing prevalence of cigarette use in theUnited States, lung cancer remains the leading cause of
cancer death.1 Patients with early-stage disease, who repre-
sent a minority of patients with lung cancer, are most com-
monly treated surgically. Recent studies have shown a sur-
vival benefit for adjuvant chemotherapy in patients with
resected non-small cell lung cancer (NSCLC), namely those
with involved regional lymph nodes and possibly with tumors
greater than 4 cm.2,3 Postoperative radiation therapy (RT) is
typically recommended for patients with resected N2 disease,
given the relatively high risk of local recurrence, with or
without chemotherapy.4–7
The International Association for the Study of Lung
Cancer recently recommended changes to the staging system
for NSCLC.8–12 T and M classification modifications have
been proposed based on an analysis of a large international
database compiled specifically to review the lung cancer
staging system; no changes were made to the N classification.
These changes have been validated, both internally and ex-
ternally, against the Surveillance, Epidemiology, and End
Results database and have shown to be prognostic for overall
survival.12 The International Association for the Study of
Lung Cancer published their 7th edition of the tumor, node,
metastasis (TNM) classification for lung cancer in 2009,13
which was developed in collaboration with the American
Joint Committee on Cancer and the Union Internationale
Contre le Cancer.
Although it has been shown that the latest TNM staging
system is predictive for overall survival, it is unclear whether
the new system is also predictive for local/regional recurrence
(LRR). Given the controversies regarding the use of adjuvant
therapies, particularly postoperative RT, for patients with
resected NSCLC, predictive tools to better define those at
increased risk for LRR would be beneficial. For most malig-
nancies, increasing stage is generally associated with a higher
risk of disease recurrence. Data for LRR rates in operable
patients with NSCLC are limited. We have previously de-
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scribed our patterns of failure in a large patient cohort.14 The
goal of this study is to directly compare the new lung staging
system (TNM 7) with the previous edition of the TNM
staging classification using a large single-institution cancer
center database.
MATERIALS AND METHODS
This institutional review board-approved study in-
cluded patients who underwent surgery for N0-N2 NSCLC at
Duke University between 1995 and 2005. Various subsets of
patients were excluded given the purpose of the present
analysis. As sublobar resections were associated with a
higher risk of local recurrence in the Lung Cancer Study
Group randomized trial,15 204 patients who underwent a
wedge resection or segmentectomy were excluded. Similarly,
23 patients with a positive bronchial, vascular, or parenchy-
mal surgical margin after lobectomy or pneumonectomy were
excluded. Patients who received chemotherapy (n  64) or
RT (n  10) as part of their initial management were also
removed from the analysis as both decrease the risk of local
recurrence.16,17 Finally, patients were excluded if they pre-
sented with superior sulcus tumors (n  30) or with chest
wall involvement (n  48). Some patients within the cohort
were excluded for more than one reason. Therefore, the
evaluation was performed with a patient population who
underwent optimal surgery without adjuvant therapy.
Medical records and pertinent radiographs were re-
viewed to obtain patient demographics, review surgical re-
ports and pathology, and to determine patterns of failure after
surgery. Each patient was staged using both the TNM 6th
edition (TNM 6)18 and 7th edition (TNM 7).19
Patterns of failure were determined by postsurgical
imaging studies and data obtained from invasive procedures,
such as bronchoscopy, mediastinoscopy, or computed tomog-
raphy-guided biopsies. LRR was defined as disease recur-
rence at the surgical margin, ipsilateral hilum, and/or medi-
astinum. Radiographic hilar and mediastinal lymph node
recurrences were defined as enlarging lymphadenopathy mea-
suring 1 cm on the short axis by computed tomography
and/or hypermetabolic lymph nodes on positron emission
tomography, which in the patient’s subsequent history was
consistent with a local recurrence. Thus, a borderline en-
larged lymph node, increased thickening at the resection
margin, or equivocal findings on positron emission tomogra-
phy were not scored as a LRR. Disease recurrence in the
contralateral hilum, supraclavicular fossae, ipsilateral lung
parenchyma, or elsewhere was defined as a distant recur-
rence. A second primary tumor was scored when a patient
presented with a new histology or the same histology but a
clinical presentation that was consistent with a new primary
tumor. All cases of suspected LRR, distant recurrence, and
development of second primary lung malignancies were re-
viewed by three authors (J.M.P., J.B., and C.R.K.), to reach a
consensus opinion and improve accuracy.
Statistical Analysis
The Kaplan-Meier method was used to estimate 5-year
LRR probabilities and 95% confidence intervals. Time to
LRR was calculated from date of surgery to the date of local
treatment failure for all patients. Patients who developed a
second primary tumor were censored on the date the second
primary tumor was diagnosed. Time to distant metastases was
also evaluated and calculated in a similar manner. All statis-
tical tests were two sided, and a p value of less than 0.05 was
considered statistically significant. Analysis was performed
using SAS 9.1 software (SAS Institute, Cary, NC).
In addition, a Cox regression analysis was performed
whereby the hazard ratio of LRR of one stage was compared
with the succeeding stage (i.e., IA–IB, IB–IIA, and IIA–IIB).
This was done independently for TNM 6 and TNM 7 to
further evaluate whether the newer staging system better
partitions the risk of LRR after surgery between each stage
group. Similar findings were obtained when pairwise com-
parisons were evaluated using a log-rank (Mantel-Cox) test.
RESULTS
Of 1088 patients who underwent surgery during the
time interval, 709 patients were eligible for the present
analysis. Median follow-up was 32 months (range: 1–174). A
total of 576 patients (81%) were pathologic N0 (pN0), 110
(16%) were pN1, and 23 (3%) were pN2. Patient, surgical,
and pathological characteristics are reported in Table 1. Stage
distribution for both TNM 6 and TNM 7 is listed in Table 2.
Local disease recurrence was identified in 100 patients.
This was confirmed pathologically in 46%. The 5-year actu-
arial risk of LRR for the entire patient cohort was 23% (95%
confidence interval: 19–26%).
Conversion from TNM 6 to TNM 7 resulted in stage
migration in 21% of patients (13% upstaging and 8% down-
staging) (Figure 1). Most upstaging involved TNM 6 stage
IB, where 22% and 8% of cases migrated to TNM 7 stage IIA
and stage IIB, respectively. In other words, patients with
larger primary tumors (5 cm) without regional lymph node
involvement migrated to stage II in TNM 7. Most downstag-
ing involved TNM 6 stage IIB, where 77% of cases migrated
to TNM 7 stage IIA. Thus, patients with hilar lymph node
involvement, but with smaller primary tumors between 3 and
5 cm, were downstaged in TNM 7.
When analyzed by stage, the 5-year actuarial risks of
LRR for stages IA, IB, IIA, IIB, and IIIA were 16%, 26%,
43%, 35%, and 40%, respectively, using TNM 6 (Figure 2).
According to TNM 7, the 5-year LRR rates were 16%, 23%,
37%, 39%, and 30%, respectively (Figure 3).
With TNM 6, the HR for LRR was statistically differ-
ent for stage IA compared with IB (p 0.001). Nevertheless,
there was no statistical difference between the other stages
using a Cox regression analysis. With TNM 7, the HR for
LRR was statistically different for IA and IB (p  0.009) as
well as IB and IIA (p  0.006). There was no difference
between IIA and IIB (p 0.792) or IIB and IIIA (p 0.589).
We also evaluated the risk of developing distant me-
tastases according to TNM 6 and TNM 7. When analyzed by
stage, the 5-year actuarial risks of developing distant metas-
tases for stages IA, IB, IIA, IIB, and IIIA were 16%, 36%,
64%, 49%, and 85%, respectively, using TNM 6. According
to TNM 7, the corresponding 5-year rates were 16%, 28%,
56%, 53%, and 65%, respectively.
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DISCUSSION
For healthy patients with early-stage NSCLC, the pre-
ferred treatment is initial surgical resection, with or without
adjuvant chemotherapy and/or RT. Recent randomized trials
have demonstrated that adjuvant cisplatin-based chemother-
apy improves overall survival in stages II to IIIA
NSCLC.17,20,21 The role of adjuvant RT remains controver-
sial. Because of the findings of the postoperative RT (PORT)
meta-analysis, which showed a survival detriment in N0 and
N1 disease, adjuvant RT is not routinely recommended for
patients without lymph node involvement or when disease
has spread to hilar lymph nodes.16 Adjuvant RT is generally
recommended for patients with resected IIIA (N2) disease
given the high risk of local disease recurrence with surgery
alone when mediastinal lymph nodes are involved. Neverthe-
less, our group and others have demonstrated that the risk of
local recurrence is relatively high in subsets of patients with
N0 to N1 disease.14,22 The purpose of this study was to
determine whether the revised staging system for lung cancer
was a better predictor of local recurrence after surgery for
NSCLC.
Our study demonstrates that LRR increases monotoni-
cally for stage I and stage II lung cancer using the new
American Joint Committee on Cancer staging system (Fig-
TABLE 1. Patient and Treatment Characteristics (N  709)
Characteristics No. Value Percentage
Age (yr)
Median 67
Range 20–92
Gender
Male 393 55
Female 316 45
Race
White 598 84
Black 91 13
Other 20 3
Surgical procedure
Lobectomy (or bilobectomy) 625 88
Sleeve resection 24 3
Pneumonectomy 60 8
Surgical approach
Open 474 67
VATS 235 33
Hilar lymph node sampling
Yes 651 92
No 58 8
Mediastinal lymph node sampling
Yes 642 91
No 67 9
Size (cm)
Median 2.9
Range 0.3–13
Histology
Adenocarcinoma 317 45
Squamous cella 264 37
Large cell 34 5
Bronchioloalveolar 22 3
NSCLC NOS 68 10
Histologic differentiation
Well 55 8
Moderate 317 45
Poor 199 28
NS 138 19
Lymphovascular space invasion
Yes 143 20
No/NS 566 80
Visceral pleural invasion
Yes 129 18
No/NS 580 82
aIncluding adenosquamous (n  4).
VATS, video-assisted thoracoscopic surgery; NOS, not otherwise specified; NS, not
stated; NSCLC, non-small cell lung cancer.
TABLE 2. Stage Distribution (TNM 6 and TNM 7)
TNM 6 No. TNM 7 No.
T1 N0 307 T1a N0 181
T1b N0 126
T2 N0 269 T2a N0 182
T2b N0 59
T3 N0 N/A T3 N0 28
T1 N1 33 T1a N1 15
T1b N1 18
T2 N1 77 T2a N1 59
T2b N1 12
T3 N1 N/A T3 N1 6
T1 N2 11 T1a N2 4
T1b N2 7
T2 N2 12 T2a N2 7
T2b N2 3
T3 N2 N/A T3 N2 2
TNM, tumor, node, metastasis; NA, not applicable.
FIGURE 1. Stage migration from TNM 6 to TNM 7 is illus-
trated. The pie chart indicates distribution by stage within
TNM 6. The bars indicate redistribution within TNM 7.
Note: all patients with TNM 6 stages IA, IIA, and IIIA re-
mained within the same stage group in TNM 7; all stage
migration occurred within TNM 6 stages IB and IIB.
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ures 2 and 3). The LRR for stage II disease (based on TNM
7) in our patient cohort approached 40%, which is certainly
high enough to warrant further investigation of postoperative
RT. There remains a reluctance to use postoperative RT due
to findings from the PORT meta-analysis and other retrospec-
tive studies.16,23 Nevertheless, with modern treatment tech-
niques, and smaller, more conformal radiation fields, the
potential benefit of modern RT may outweigh the risks when
rates of local recurrence are this high. Indeed, two random-
ized prospective studies published after the PORT meta-
analysis suggest that the use of more conformal/limited RT
fields may improve outcomes in patients with resected
NSCLC.24,25
The LRR rates for IIIA disease using TNM 6 and TNM
7 were 40% and 30%, respectively. Nevertheless, we only
had a small number of patients with pathologic N2 disease
who did not receive any adjuvant therapy. Further, it is not
surprising that the overall risk of local recurrence would
decrease if more patients with N1 disease are combined with
patients with N2 disease. In TNM 7, patients with large (7
cm) primary tumors with N1 involvement are now classified
as IIIA.
Reported actuarial rates of local failure after surgery for
NSCLC vary in the literature. For example, reported local
failure rates vary from 6 to 45% in studies examining stage I
NSCLC.15,25–32 These discrepancies are likely multifactorial,
including differing definitions of LRR, diligence in which
local recurrence is evaluated and scored, and the use of crude
rates as opposed to actuarial rates. Additionally, many studies
report only first sites of failure. Distant recurrences are easier
to assess clinically and radiographically than LRR, and thus,
rates of local failures can be underreported. In our study, the
overall actuarial LRR rate was 23% in a population of
patients who underwent either lobectomy or pneumonectomy
and did not receive neoadjuvant or adjuvant therapy.
There are many strengths of this analysis. This is one of
the largest studies examining rates of local failure with more
than 700 patients examined. This is after excluding many
patients with confounding variables: sublobar resections, pos-
itive surgical margins, or any RT or chemotherapy. Our
definition of local recurrence was tightly defined. Only fail-
ures at the surgical stump, ipsilateral hilum, and/or medias-
tinum were considered as a LRR. Several studies have used
broader definitions of LRR, including any failures within the
ipsilateral lung. By contrast, our definition only includes sites
that are encompassed within a typical postoperative RT field,
thus making our data more informative in the design of future
studies of adjuvant therapy.
Our analysis has the limitations common to most ret-
rospective studies. First, pathological and clinical data were
not collected prospectively, thus increasing the possibility of
errors within the database. Second, patients were treated
during an 11-year time interval with somewhat variable
approaches. Nevertheless, the studied patients were all uni-
formly treated with surgery alone; patients who received any
adjuvant chemotherapy or RT were excluded. Third, not all
patients had pathologic confirmation of local disease recur-
rence. The remaining were confirmed using radiographic
studies. Although this may overestimate rates of LRR recur-
rence, we did our best to verify each case of recurrence by
having three physicians review each local failure. Despite
this, however, errors may have been made. Finally, some of
our subgroups, particularly those with IIIA disease, contained
only a modest number of patients. This decreased the power
of our analyses.
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FIGURE 2. Kaplan-Meier curve of time to local/regional re-
currence based on stage, TNM 6.
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FIGURE 3. Kaplan-Meier curve of time to local/regional re-
currence based on stage, TNM 7.
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CONCLUSION
The TNM 7 system seems to be a better predictor for
LRR after surgery for NSCLC than TNM 6. This information
may prove to be valuable when designing future studies of
postoperative RT.
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